Seeking Alpha

The FDA extends its review of Biogen Idec's (BIIB -2.8%) multiple-sclerosis pill BG-12 by three...

The FDA extends its review of Biogen Idec's (BIIB -2.8%) multiple-sclerosis pill BG-12 by three months, although the agency hasn't requested additional studies. Last week, Biogen said that new data provided more evidence of the the drug's effectiveness in patients with relapsing-remitting MS.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|